Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review [PDF]
, 2020 This narrative review aims to provide an overview of the current literature on thepharmacology, safety, efficacy and tolerability of intranasal esketamine, the S-enantiomerof ketamine, for the treatment of treatment-resistant depression (TRD).
Peterson, GM, Salahudeen, MS, Wright, CM
core +2 more sources
Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees [PDF]
, 2022 Background Esketamine was licensed for use in treatment resistant depression by the European Medicines Agency in December 2019. It is unclear whether this new approval has lowered the risk perception of recreational ketamine use.
Curran, H. Valerie +4 more
core +2 more sources
A deep learning‐enabled toolkit for the 3D segmentation of ventricular cardiomyocytes
The Journal of Physiology, EarlyView.Abstract figure legend 3D cardiomyocyte segmentation enables comprehensive analyses of myocardial microstructure in health and disease; however, it is technically demanding. We present an open‐source toolkit for this task, which reduces challenges associated with sample preparation, image restoration, segmentation and proofreading.
Joachim Greiner +6 more
wiley +1 more source
Paediatric and Neonatal Pain, Volume 8, Issue 2, June 2026.ABSTRACT Progressive hip displacement is a common problem in children with neurodevelopmental conditions, often leading to painful dislocation and impaired function. Hip reconstruction may be necessary to maintain containment but these reconstructions are major surgery in this vulnerable population.
Renée A. van Stralen +5 more
wiley +1 more source
Acta Psychiatrica Scandinavica, Volume 153, Issue 6, Page 610-626, June 2026.ABSTRACT Introduction Suicide risk is markedly elevated following presentation after self‐harm, yet the evidence base for interventions initiated in the immediate post‐presentation period has not been synthesized with specific attention to this high‐risk window. Clarifying which early interventions may reduce adverse outcomes is essential for informing
Guilherme Pimenta Roncete +7 more
wiley +1 more source
Addiction, Volume 121, Issue 6, Page 1616-1621, June 2026.Abstract Revived interest in psychedelic‐assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti‐addictive potential. Evidence from observational, open‐label, and limited randomized placebo‐controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in ...
Tibor Markus Brunt
wiley +1 more source
Esketamine vs. placebo combined with erector spinae plane block vs. intercostal nerve block on quality of recovery following thoracoscopic lung resection: A randomized controlled factorial trial. [PDF]
Multimodal analgesic strategy is pivotal for enhanced recovery after surgery. The objective of this trial was to assess the effect of subanesthetic esketamine vs. placebo combined with erector spinae plane block (ESPB) vs.
Chen, Shaomu +10 more
core +1 more source
Esketamine use in real-world clinical practice in patients with treatment-resistant depression
European PsychiatryBackground Esketamine has been shown to produce a major antidepressant response in patients with treatment-resistant depression (TRD). We evaluated the factors associated with achieving remission in these individuals.
Ismael Conejero +9 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 953-963, April 2026.Grapefruit juice is a well‐established inhibitor of cytochrome P450 (CYP) 3A4, but its effects on other CYP enzymes or organic anion transporting polypeptides (OATPs) are not fully characterized in humans. Recently, lingonberry powder was shown to induce murine CYP enzymes. We investigated the effects of lingonberry powder and grapefruit juice on seven
Laura Aurinsalo +7 more
wiley +1 more source
The Resistant Depression Response to Esketamine Assessing Metabolomics (ReDREAM) Project-Untargeted Metabolomics to Identify Biomarkers of Treatment Response to Intranasal Esketamine in Individuals with Treatment-Resistant Depression: A Study Protocol [PDF]
Objective: Treatment-resistant depression (TRD) affects around 20-30% of people with major depressive disorder. In 2019, esketamine nasal spray was approved for TRD by both the US Food and Drug Administration and the European Medicines Agency.
Albert, Umberto +9 more
core +1 more source